CS
Christine Shaw
VP, Assay Development

Christine Shaw insider trades: GenMark Diagnostics (GNMK) stock sales

VP, Assay Development, GenMark Diagnostics Last trade Mar 5, 2021 12 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
9
Open-market trades
since 2020
1
Company
last trade 2021

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Christine reports to the SEC

Open-market buys and sales

9 trades reported on SEC Form 4, newest first

DateStockTypeValue
Mar 5, 2021GNMK↓ Sell$5K
Feb 26, 2021GNMK↓ Sell$54K
Feb 24, 2021GNMK↓ Sell$8K
Jan 27, 2021GNMK↓ Sell$1K
Dec 7, 2020GNMK↓ Sell$4K
Nov 24, 2020GNMK↓ Sell$5K
Oct 27, 2020GNMK↓ Sell$771
Sep 8, 2020GNMK↓ Sell$3K
Aug 25, 2020GNMK↓ Sell$5K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Christine Shaw's insider trades

Christine Shaw is VP, Assay Development at GenMark Diagnostics (GNMK). Since Aug 25, 2020, Christine has reported no open-market purchases and 9 sales worth $86K on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include other transactions (1 filing), shares returned to the company (1 filing), shares withheld for taxes (1 filing), grants and awards (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every GNMK insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.